🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

EE268 Temporal Trends in Adverse Event Costs with Nivolumab + Relatlimab Combination Therapy or Nivolumab Monotherapy for Patients with Unresectable or Metastatic Melanoma

Value in Health(2023)10.1016/j.jval.2023.03.569Source: DataRank Database

EE268 Temporal Trends in Adverse Event Costs with Nivolumab + Relatlimab Combination Therapy or Nivolumab Monotherapy for Patients with Unresectable or Metastatic Melanoma is a research paper published in Value in Health (2023). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

0 citations

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:OA: bronzeTopics (14)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Z.Y. Zhou,A. Moshyk,L.C. Rosenblatt,D. Patel ORCID,Y. Xin ORCID

Live enrichment

PubMed:19162232 OpenAlex:https://openalex.org/W4380150279

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.valueinhealthjournal.com/article/S1098301523006691/pdf

publisherhttp://www.valueinhealthjournal.com/article/S1098301523006691/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1098301523006691?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1098301523006691?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jval.2023.03.569

Fields of Study

CAR-T cell therapy researchCancer Immunotherapy and BiomarkersHealth Systems, Economic Evaluations, Quality of Life

Keywords

NivolumabMedicineMetastatic melanomaAdverse effectOncologyCombination therapyInternal medicineMelanomaImmunotherapyCancerCancer research

Sustainable Development Goals

SDG 0: Good health and well-being